Primary screening found that ChaC1 overexpression mediated glutathione depletion dramatically enhanced the anti-cancer effect of auranofin (AUR), a gold (I)-containing compound approved by FDA since 1980’s to treat rheumatoid arthritis (RA) [15]. Here, CHAC1 is linked to rheumatoid arthritis.